{"rewrite":{"id":"r_368bbe946be9a62cc8fed0ee","clusterId":"c_c24e4656d900b5ce8409cc05","slug":"openai-acquires-orchestra-bio-to-build-out-life-sciences-ai","model":"deepseek-v4-1-flash","headline":"OpenAI Acquires Orchestra Bio to Build Out Life Sciences AI","summary":"OpenAI has acquired Orchestra Bio, a company founded in 2022 that supplies AI agents for managing the drug discovery process. The price is undisclosed; Orchestra Bio had raised about $20 million from venture firms including Andreessen Horowitz as of 2025. OpenAI will fold the team and technology into Rosalind, its AI models and tools for life sciences research, and called the integration a first step toward AI assisting scientists from discovery through development.","whyItMatters":"OpenAI is buying a working drug-discovery operation rather than building one, and folding the team into Rosalind gives its life sciences models a process to run on rather than a benchmark to pass.","webCardHtml":"\u003cp\u003eThe acquisition gives Rosalind something beyond a model: a team that already runs AI agents across discovery work. Orchestra Bio was founded in 2022 and raised roughly $20 million from backers including Andreessen Horowitz as of 2025; OpenAI did not disclose what it paid.\u003c/p\u003e\u003cp\u003eOpenAI framed the combination as a starting point, describing a goal of AI helping scientists explore ideas, design experiments, analyze results, and coordinate the operations that move a promising treatment forward. The company says it wants to work with researchers and partner companies on that path.\u003c/p\u003e","blueskyPost":"Orchestra Bio raised about $20 million and now ships inside Rosalind. OpenAI is buying small teams with existing agent products rather than building the drug discovery workflow itself.","twitterPost":"Orchestra Bio raised about $20 million and now folds into Rosalind. OpenAI is buying small agent teams rather than building drug discovery itself.","threadsPost":"Orchestra Bio, founded in 2022 with about $20 million raised, now folds into Rosalind. OpenAI is assembling life sciences AI from small agent startups, not from a research division of its own. The undisclosed price leaves the cost of that build-out unmeasured.","newsletterBlurb":"OpenAI has bought Orchestra Bio, a company founded in 2022 that runs AI agents across the drug discovery process. The team and technology go into Rosalind, OpenAI's models and tools for life sciences research. OpenAI did not disclose the price; Orchestra Bio had raised about $20 million from investors including Andreessen Horowitz as of 2025.","attributionJson":"[{\"source\":\"GIGAZINE\",\"url\":\"https://gigazine.net/news/20261021-openai-acquires-orchestra-bio/\",\"title\":\"OpenAI acquires drug development platform Orchestra Bio\"}]","lintFlagsJson":null,"lintHits":0,"costUsd":0,"inputTokens":4612,"outputTokens":558,"status":"published","repairAttempts":0,"nextRepairAt":null,"factsAttemptedAt":1792563728,"createdAt":"2026-10-21T06:17:33.000Z","publishedAt":"2026-10-21T06:21:07.000Z","updatedAt":"2026-10-21T06:21:07.000Z"},"cluster":{"id":"c_c24e4656d900b5ce8409cc05","canonicalTitle":"OpenAIが医薬品開発プラットフォームのOrchestra Bioを買収","representativeArticleId":"a_7ebc1b9a2f1525a6f72ea646","sourceCount":1,"writtenSourceCount":1,"writeAttempts":0,"isSolo":true,"entitiesJson":"{\"anime_titles\":[],\"manga_titles\":[],\"work_titles\":[],\"studios\":[],\"people\":[],\"type\":\"business\",\"domain\":\"other\",\"is_roundup\":false}","contentType":"news","status":"published","firstSeenAt":"2026-10-21T01:46:00.000Z","lastSeenAt":"2026-10-21T01:46:00.000Z","updatedAt":"2026-10-21T06:21:07.000Z"},"attribution":[{"source":"GIGAZINE","url":"https://gigazine.net/news/20261021-openai-acquires-orchestra-bio/","title":"OpenAIが医薬品開発プラットフォームのOrchestra Bioを買収"}],"entities":{"anime_titles":[],"manga_titles":[],"work_titles":[],"studios":[],"people":[],"type":"business","domain":"other","is_roundup":false},"keyFacts":null}